Results 81 to 90 of about 1,869 (168)

Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis

Frontiers in Pharmacology
BackgroundLebrikizumab, an IL-13 immunomodulator, has shown recommendable effectiveness and safety in clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults.ObjectiveTo evaluate the efficacy and safety ...
Jinger Lin, Min Luo, Qianwei Zhuo, Nuo Chen, Haosong Zhang, Yue Han   +5 more
doaj   +1 more source

Advances in Atopic Dermatitis Management: The Role of Lebrikizumab

Dermatologic Therapy
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by intense pruritus and eczematous lesions, significantly impacting patients’ quality of life. Current treatment options include topical therapies (e.g., corticosteroids, calcineurin inhibitors, and topical Janus kinase [JAK] inhibitors), phototherapy, and systemic ...
Saba Mushtaq, Hafsa Shuja, Hamza Yousuf Ibrahim, Syeda Farwa Zehra, Umer Wamiq, Muhammad Faisal, Fawaz Ur Rehman, Ayesha Abdullah, Ehsanullah Alokozay   +8 more
openaire   +1 more source

Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease for which signs and symptoms have a negative impact on a patient’s quality of life (QoL) and mental health.
Peter A. Lio, April Armstrong, Jan Gutermuth, Audrey Nosbaum, Howard Sofen, Esther Garcia Gil, Marta Casillas, Sherry Chen, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Zach Dawson, Tiago Torres   +12 more
doaj   +1 more source

Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement

Dermatology Reports
Lebrikizumab, an anti-interleukin (IL)-13 monoclonal antibody, is a promising treatment for moderate-to-severe atopic dermatitis (AD). We conducted a single-center, retrospective study in 21 adults with moderate-to-severe AD who were biologic-naïve and ...
Edoardo Mortato, Claudia Paganini, Marina Talamonti, Virginia Maffei, Alfredo Belcastro, Cosimo Di Raimondo, Lorenzo Tofani, Luca Bianchi, Marco Galluzzo   +8 more
doaj   +1 more source

Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis

Journal of Dermatological Treatment
Purpose of the study Head, neck (HN), and face involvement in atopic dermatitis (AD) poses a major psychological burden and can be challenging to effectively treat.
Jenny E. Murase, Kilian Eyerich, Raj Chovatiya, H. Chih-ho Hong, Christine Bangert, Lindsay Strowd, Mette Deleuran, Amber Reck Atwater, Maria Jose Rueda, Hany Elmaraghy, Maria Lucia Buziqui Piruzeli, Ignasi Pau-Charles, Fan Emily Yang, Jinglin Zhong, Delphine Staumont-Sallé   +14 more
doaj   +1 more source

Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials [PDF]

Introduction: Lebrikizumab significantly reduced itch and itch interference on sleep in patients with moderate-to-severe atopic dermatitis (AD) at week 16 in two phase 3 trials.
Serra Baldrich, Esther, Casillas, Marta, Carrascosa, José Manuel, Ständer, Sonja, Lio, Peter, Lio, Peter A., Legat, Franz J., Zhong, Jinglin, Rosmarin, David, Universitat Autònoma de Barcelona. Departament de Medicina, Elmaraghy, Hany, Crane, Heidi, Yosipovitch, Gil, Serra-Baldrich, Esther, Pierce, Evangeline, Carrascosa, Jose-Manuel, Legat, Franz Josef, St\ue4nder, Sonja, Bardolet, Laia   +18 more
core   +1 more source

67 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS

Dermatology Reports
Background and Objectives. To evaluate the efficacy and safety of lebrikizumab compared to placebo (PBO) in patients 6 months to
Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica
doaj   +1 more source

Long-term efficacy of lebrikizumab in treating head, neck and face involvement in patients with moderate-to-severe atopic dermatitis

Journal of Dermatological Treatment
Objectives: Head, neck, and face (HNF) atopic dermatitis (AD) substantially impairs quality of life, yet long-term biologic efficacy data in HNF areas remain limited.Methods: This post hoc analysis evaluates HNF efficacy of lebrikizumab across phase 3 ...
Raj Chovatiya, Marjolein de Bruin-Weller, Andrew Alexis, Chesahna Kindred, Mona Shahriari, Jill Waibel, Christian Vestergaard, Natalie Nunez Gomez, Khai Jing Ng, Lucia Seminario-Vidal, Zach Dawson, Chao Yang, Yuxin Ding, Julien Seneschal   +13 more
doaj   +1 more source

Successful Lebrikizumab Therapy in Two Patients With Atopic Dermatitis Resistant to Multiple Therapies

JEADV Clinical Practice
The treatment landscape for moderate‐to‐severe atopic dermatitis (AD) has evolved significantly with the introduction of novel targeted therapies addressing specific pathogenic mechanisms of the disease.
Elena Ippoliti, Niccolò Gori, Benedetta Ambrosio, Giulia Coscarella, Maria Vittoria Cannizzaro, Ketty Peris   +5 more
doaj   +1 more source

Lebrikizumab [PDF]

, 2020
openaire   +1 more source